Vaxart, Inc. (VXRT)

Vaxart Q2 Earnings Call Highlights

Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now

Vaxart to Participate in BTIG Biotechnology Conference 2026

Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now

Vaxart Announces Results of Annual Meeting of Stockholders

Vaxart Announces Results of Annual Meeting of Stockholders

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements

Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders